pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
HER2 · news · pharmadog
← back to HER2
News · HER2
124
stories
May 12, 26
Future Directions in Relapsed and Refractory Multiple Myeloma
onclive
May 12, 26
Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer
onclive
May 12, 26
Sequencing Strategies After Progression in Multiple Myeloma
onclive
May 12, 26
EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy
onclive
May 12, 26
Sequencing ADCs in Endometrial Cancer
onclive
May 12, 26
Second Clinical Scenario - Progressive Disease Despite Hematocrit Control
onclive
May 11, 26
Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
onclive
May 11, 26
MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
onclive
May 11, 26
Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT
onclive
May 11, 26
Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection
onclive
May 11, 26
Expanding ctDNA Applications to RCC and Germ Cell Tumors
onclive
May 11, 26
RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice
onclive
May 11, 26
ctDNA in Metastatic Urothelial Carcinoma
onclive
May 11, 26
Institutional Perspectives on Treatment Thresholds in PLGG
onclive
May 11, 26
Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups
onclive
May 10, 26
Five Under 5: Top Oncology Videos for the Week of 5/3
onclive
May 9, 26
The OncFive: Top Oncology Articles for the Week of 5/3
onclive
May 8, 26
Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT
onclive
May 8, 26
Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
onclive
May 8, 26
Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
onclive
May 8, 26
Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD
onclive
May 8, 26
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
onclive
May 8, 26
FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
onclive
May 8, 26
UT MD Anderson Shares Latest Research Breakthroughs
onclive
May 8, 26
Giants of Cancer Care Announces the 14th Annual Class of Inductees
onclive
May 8, 26
OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer Updates
onclive
May 8, 26
OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
onclive
May 8, 26
Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
onclive
May 8, 26
Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL
onclive
May 8, 26
Characterization and Management of Sevabertinib induced Diarrhea in the SOHO 1 study
onclive
← prev
page 3 of 5
next →
